IMPORTANCE Sensorineural hearing loss (SNHL) is commonly caused by conditions that affect cochlear structures or the auditory nerve, and the genes identified as causing SNHL to date only explain a fraction of the overall genetic risk for this debilitating disorder. It is likely that other genes and mutations also cause SNHL.
H earing loss is one of the most common sensory defects in humans, affecting approximately 1 in 1000 newborns, with an estimated 50% having genetic causes. 1, 2 Incidence of hearing loss is estimated as 0.5% in older children (aged 3-17 years) 3 and 17% in adults. 4 Sensorineural hearing loss (SNHL) is caused by conditions that affect the cochlear structures or the auditory nerve. In addition to genetic factors, environmental insults contribute to the development of SNHL. [5] [6] [7] [8] A large number of genetic loci have been identified that contribute to autosomal dominant, autosomal recessive, X-linked, Y-linked, and mitochondrial forms of nonsyndromic SNHL. 9 Fifty-three independent genetic loci contributing to nonsyndromic autosomal dominant SNHL have been discovered, with 142 mutations in 31 genes identified. Similarly, more than 76 loci contribute to recessive forms of SNHL. However, those identified to date only explain a fraction of the overall genetic risk for SNHL, and more remain to be discovered. Recommendations and outcomes of SNHL habilitation, such as hearing aids and cochlear implants, depend on myriad factors, and advances in genetic testing can provide useful etiologic information to aid clinical decisions. Initiatives to incorporate genetic testing in early hearing detection and intervention programs aim to inform the cause of congenital hearing loss in newborns and the risk of late-onset hearing loss in children. 10, 11 Although clinical testing is expanding to identify mutations, much is still unknown about the genetic causes and molecular mechanisms of progressive SNHL, and the effect of genetic testing on clinical management of SNHL remains limited. The objective of this study was to identify a candidate gene causing bilateral, symmetric, progressive SNHL in a multigeneration family of Northern European descent. Our analyses identified a sequence variant in a previously uncharacterized gene, TMTC2 (OMIM 615856) , that is strongly associated with SNHL in this family. The gene variant is also associated with SNHL in a group of unrelated individuals, suggesting that TMTC2 may be of broader importance for normal auditory function.
Methods

Study Participants
Family members were recruited in Wisconsin and adjacent Midwestern US states from January 1, 2006, through April 1, 2016. All were of Northern European descent. Hearing loss status was reported by family members (for deceased and very young individuals), self-reported, or clinically assessed by standard audiometric testing. All available audiograms were used to calculate age-related typical audiograms, as described by Topsakal and colleagues. 12 Octave-frequency threshold values of the right ear were plotted by age and frequency-specific linear regression equations used to calculate threshold values for each decade of age from 0 to 70 years, which were then transposed to generate age-related typical audiograms. In addition, unrelated adult volunteers of Northern European descent with confirmed SNHL requiring a cochlear implant or hearing aids were included who were patients of, or referrals to, our clinical program. A control group of adults of Northern European descent from the Midwestern US states who self-reported as not having deafness was also included.
All procedures were approved by the Children's Hospital of Wisconsin Institutional Review Board. Written informed consent was obtained from all study participants for this study and for publication. Data were deidentified for genetic analyses but not for phenotypic analyses.
DNA Sample Collection
DNA was obtained from saliva, buccal swabs, or blood using Oragene Collection Kits and Oragene prepIT-LP2 reagent (DNA Genotek) for saliva, Isohelix T-Swabs (Boca Scientific) and PUREGENE DNA Isolation Kit (Gentra Systems) for buccal swabs, and the whole-blood PUREGENE DNA Isolation Kit (Gentra Systems) for blood. Extracted DNA was resuspended in Tris-EDTA buffer and stored at −20°C.
Linkage Analysis
DNA samples were genotyped using the Human SNP Array 6.0 (Affymetrix). Data were analyzed using the Genotyping Console software suite (Affymetrix) with default parameters. Any genotype that was inconsistent with mendelian segregation was blanked using SimWalk2. 13 A subset of markers was selected for linkage analysis to minimize the linkage disequilibrium (LD) between adjacent variants. Only single-nucleotide polymorphisms (SNPs) with a minimal distance between markers of 25 000 bp and a minimum minor allele frequency of 0.25 were included. Twopoint linkage analysis using 61 108 SNP markers was conducted in Sequential Oligogenic Linkage Analysis Routines (SOLAR) 14 using a probit liability model with ascertainment correction. 15 
Resequencing
Six family members were analyzed by exome sequencing using the Agilent SureSelectXT All Exon V5 Target Enrichment System (affected individuals III:7, IV:6, IV:9, V:7, and V:11 and unaffected individual III:8 We initially analyzed a large multigeneration family of Northern European descent with a likely autosomal dominant form of bilateral, symmetric, progressive SNHL reaching severe to profound loss of hearing in childhood ( Figure 1) . Figure 2A and B show examples of the audiometric configuration and progression of hearing loss with age for family members III:7 and V:7 (right ear only). Figure 2C shows examples of available audiometric data for 3 of the unrelated individuals with SNHL of various ages who were ultimately found to have the same genetic mutation as the Wisconsin family (right ear only). Age-related typical audiograms from the Wisconsin family demonstrated progressive, high-frequency sloping hearing loss with a characteristic dip at 1000 to 2000 Hz and peak at 4000 Hz ( Figure 2D ).
The exact ages at hearing loss onset were not determinable; however, the earliest available audiograms and medical records were analyzed for the 9 individuals who provided them (Table) . Clinic al record data confirmed childhood-onset hearing loss for 6 family members. For the remaining 3 individuals, childhood onset was self-reported. All affected individuals are auditory-oral communicators who wear hearing aids, and 2 family members have received unilateral cochlear implants (individuals III:7 and V:11). The 2 individuals with implants have had benefit from this intervention consistent with postlingual onset of severe to profound hearing loss.
To identify the gene causing the SNHL in this family, 20 individuals across 4 generations, including 11 affected individuals, were analyzed. Complete genotype data for all individuals were obtained on 631 644 variants. Two-point linkage analysis identified a region on chromosome 12q21 (logarithm of odds [LOD], 3.3) (Figure 3) . The 1 − LOD CI spans 13 Mb (79-92 Mb, GRCh37/hg19) and contains 48 known genes. Three individual SNPs were strongly linked to SNHL (LOD, >3), and 53 additional SNPs had suggestive evidence of linkage (LOD, >2). None of the genes in this region has been implicated in autosomal dominant hereditary hearing loss, 9 and the linkage region does not overlap with any other SNHL loci. However, the region contains 2 genes, PTPRQ (OMIM 603317) and OTOGL (OMIM 614925), that have been identified at the DFNB84 locus, causing an autosomal recessive form of SNHL. As shown in Figure 3 , the linkage analysis also uncovered a second region on chromosome 5q11.2-14.3 with suggestive evidence of linkage (LOD, 2.8). However, no evidence for linkage remains when the analysis is performed conditional on the locus on chromosome 12q (LOD, 0.18), suggesting that the locus on 12q21 harbors the causal gene for SNHL in this family.
To identify the likely causal gene in the linkage interval and to simultaneously explore the role of other previously reported loci for autosomal dominant hearing loss, we selected 6 individuals (III:7, III:8, IV:6, IV:9, V:7, and V:11) from the family for resequencing using exome capture. The sequence analysis revealed 84 357 SNP variants across the probability of 1 for the association with the single variant; no other variant tested had a posterior probability of association exceeding 0.42 (and the other variants were not in substantial LD with rs35725509). We did not uncover any putative functional (nonsynonymous) sequence variants in the genes PTPRQ and OTOGL, the 2 genes in the linkage interval previously implicated in an autosomal recessive form of SNHL (the DFNB84 locus) that matched the expected genotype distribution for the sequenced individuals. The 2 genes are more than 2 Mb away from the rs35725509 variant in TMTC2, making it unlikely that long-range LD between the variant in TMTC2 and a causal variant in either of these 2 genes led to the result we obtained in our association analysis.
To validate the association of the variant rs35725509 with SNHL in the family, we genotyped 47 individuals from the family (all 32 individuals highlighted in Figure 1 and an additional 15 unaffected descendants of individual III:5 and found a total of 13 affected individuals) and 40 control Centre d'Etude du Polymorphisme Humain DNA samples. All unaffected family members and Centre d'Etude du Polymorphisme Humain DNA samples were homozygous for the wild-type G allele, and 11 of 12 affected individuals were heterozygous. One affected individual (individual IV:7) was homozygous for the alternate A allele. Although homozygous, the hearing loss phenotype for individual IV:7 was not more severe compared with other family members (Table) . The genotypes for all 6 individuals who underwent sequencing (III:7, III:8, IV:6, IV:9, V:7, and V:11) were confirmed, and no discrepancies were uncovered between the sequencing and genotyping data. The variant revealed a strong association with SNHL (P = 6 × 10 −13 , N = 47) in the extended family, and no residual heritability remained when the variant was included in the association model, suggesting that this gene region is responsible for a fully penetrant form of autosomal dominant SNHL in this family.
Because the identified variant in TMTC2, rs35725509, has been detected in the 1000 Genomes and Exome Sequencing (http://evs.gs.washington.edu/EVS/) European call sets (1% and 0.8% frequency, respectively), it is possible that the variant may be associated with SNHL in other patients beyond the initial family. This finding is further supported by the family data because individual IV:7 is homozygous for the mutation, suggesting that her father, who married into the family, was a carrier for the mutation as well (no DNA or phenotypic information was available from this deceased individual). DNA analysis from the 179 unrelated volunteers with confirmed SNHL revealed an allele frequency for the minor A allele of 0.031, with 11 individuals being heterozygous for the sequence variant. In contrast, of the 186 patients of Northern European descent from the Midwestern United States who self-reported not having deafness, 184 were homozygous for the G allele of rs35725509 (P = 7 × 10 −4 ). Two individuals had the minor A allele; however, on follow-up to confirm hearing status, 1 individual (currently deceased) was reported by family members to have worn hearing aids, and the other individual was unable to be contacted. The combined data confirm that the variant rs35725509 is strongly associated with SNHL in both the original family and the general population; therefore, TMTC2 likely represents a novel gene affecting hearing in humans. Analysis of an expressed sequence tag profiling human gene expression database (http://www.ncbi.nlm.nih.gov /unigene/) revealed expression of TMTC2 in 21 of 45 tissues examined, including adipose tissue, kidney, heart, and intestine; however, no expressed sequence tags of TMTC2 were detected in ear tissue. Likewise, the Mouse Genome Informatics website (http://www.informatics.jax.org/) reports expression of TMTC2 in 40 different tissues but not in ear or cochlear tissue. We collected cochlear tissue samples from 3 human cadavers, and reverse transcription-polymerase chain reaction analysis confirmed robust expression of TMTC2 in these samples when compared with expression of HPRT (OMIM 308000), a gene known to be expressed in the inner ear of humans, 19 further validating the gene as a potential regulator of normal hearing function (Figure 4) . 
Discussion
Our analysis of a large family with SNHL revealed a previously uncharacterized gene that is likely to affect normal hearing and inner ear function. Interestingly, the identified variant in TMTC2, rs35725509, is strongly associated with SNHL not only in the original family but also in the general population, suggesting that the gene plays an important role in regulating and maintaining auditory function in humans. The specific function of TMTC2 is unknown, but TMTC2 is a transmembrane protein that contains 10 tetratricopeptide repeat motifs (http://www.uniprot.org/uniprot/Q8N394) and a structural motif that consists of 34 degenerate amino acids. The motif is found in a number of proteins and mediates protein-protein interaction (http://www.uniprot.org/keywords /KW-0802). A previous study 20 localized TMTC2 to the endoplasmic reticulum in HEK293 cells and found it to be associated with the endoplasmic reticulum calcium uptake pump SERCA2B, but the detailed function of the protein and its putative role in other tissues have not been elucidated. It is possible that TMTC2 is involved in a novel mechanism that affects hearing in humans.
The variant rs35725509 in TMTC2 may not actually be causing the observed hearing loss in the family because the mutation is found in a relatively high percentage of individuals of Northern European descent in the 1000 Genomes and Exome Sequencing (http://evs.gs.washington.edu/EVS/) European call sets (1% and 0.8%, respectively). The TMTC2 gene spans a genomic interval of 447 kb on human chromosome 12. The exome capture did not cover the 5′ and 3′ untranslated regions or any of the putative regulatory upstream or intronic sequences of TMTC2. The sequence variant rs35725509 is located in an LD block that spans 28 kb around exon 3 and has long-range LD with other SNPs in adjacent regions of TMTC2, suggesting that the mutation (or mutations) causing SNHL in this family may be located in other regions of the gene. However, there is no evidence that the LD extends beyond the TMTC2 gene region, and any causal variant would be located in this gene. Future studies and sequencing analyses are needed to identify the true causal sequence variant (or multiple variants) in the family and other patients with SNHL to fully assess the role of TMTC2 mutations in SNHL in the general population. Additional functional studies will need to elucidate the role of TMTC2 in normal auditory function to determine whether this novel gene may provide clues for alternative novel treatment approaches in the future.
To date, 53 loci and 31 genes have been identified in which mutations cause nonsyndromic autosomal dominant SNHL (http://hereditaryhearingloss.org). Only 2 of all the nonsynonymous mutations reported for these genes (Val306Met and Gly662Glu in MYO1A [OMIM 601478]) are found at frequencies comparable to rs35725509 in TMTC2 in the general population, as assessed from the National Heart, Lung, and Blood Institute Exome Resequencing data (1.0% and 3.8%, respectively); all others are extremely rare and often specific to a single family. The audiometric configuration and progression patterns in this family are similar to phenotypes described for DFNA2 (OMIM 603537), particularly for KCNQ4 (OMIM 603537) pore-region mutations W276S in Dutch and Japanese families 12, 21, 22 and G285C in a US family. 23 , 24 We did not identify any nonsynonymous variants that matched the expected genotypes for the included individuals in any of the other previously reported genes and loci causing autosomal dominant SNHL, including KCNQ4 at the DNFA2 locus, suggesting that a mutation in the gene TMTC2 is likely responsible for the observed hearing loss. This finding, again, suggests that this novel mutation may be an important contributor to autosomal dominant SNHL.
Conclusions
A previously uncharacterized gene, TMTC2, was identified as a candidate for causing progressive SNHL in humans. This finding provides a more detailed understanding of the genetic basis of SNHL and reveals a potentially new, uncharacterized mechanism of hearing loss. Ultimately, these results contribute to improving our diagnostic capabilities and reveal targets for more effective treatment strategies for SNHL.
